NASDAQ:SRTS

Sensus Healthcare Stock Forecast, Price & News

$3.57
+0.06 (+1.71 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.53
$3.64
50-Day Range
$3.22
$4.07
52-Week Range
$2.32
$6.09
Volume11,478 shs
Average Volume200,355 shs
Market Capitalization$59.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.47
30 days | 90 days | 365 days | Advanced Chart
Receive SRTS News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensus Healthcare and its competitors with MarketBeat's FREE daily newsletter.


Sensus Healthcare logo

About Sensus Healthcare

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

463rd out of 1,352 stocks

Surgical & Medical Instruments Industry

46th out of 123 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Sensus Healthcare (NASDAQ:SRTS) Frequently Asked Questions

Is Sensus Healthcare a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sensus Healthcare stock.
View analyst ratings for Sensus Healthcare
or view top-rated stocks.

What stocks does MarketBeat like better than Sensus Healthcare?

Wall Street analysts have given Sensus Healthcare a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sensus Healthcare wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sensus Healthcare's next earnings date?

Sensus Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Sensus Healthcare
.

How were Sensus Healthcare's earnings last quarter?

Sensus Healthcare, Inc. (NASDAQ:SRTS) posted its quarterly earnings results on Thursday, August, 5th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. The business had revenue of $5.42 million for the quarter, compared to analyst estimates of $4.07 million. Sensus Healthcare had a negative net margin of 13.60% and a negative trailing twelve-month return on equity of 10.02%.
View Sensus Healthcare's earnings history
.

How has Sensus Healthcare's stock price been impacted by Coronavirus (COVID-19)?

Sensus Healthcare's stock was trading at $3.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SRTS shares have increased by 8.0% and is now trading at $3.51.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SRTS?

4 brokers have issued 12-month price targets for Sensus Healthcare's stock. Their forecasts range from $6.00 to $7.00. On average, they anticipate Sensus Healthcare's share price to reach $6.33 in the next year. This suggests a possible upside of 80.4% from the stock's current price.
View analysts' price targets for Sensus Healthcare
or view top-rated stocks among Wall Street analysts.

Who are Sensus Healthcare's key executives?

Sensus Healthcare's management team includes the following people:
  • Joseph C. Sardano, Chairman, President & Chief Executive Officer
  • Nicolas Soro, Chief Operating Officer
  • Javier Rampolla, Chief Financial Officer
  • Russ Price, Chief Technology Officer
  • Ziv Karni, Chief Scientific Officer

Who are some of Sensus Healthcare's key competitors?

What other stocks do shareholders of Sensus Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sensus Healthcare investors own include Ring Energy (REI), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Nabriva Therapeutics (NBRV), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), Vaxart (VXRT), Amarin (AMRN), Palatin Technologies (PTN) and QUALCOMM (QCOM).

When did Sensus Healthcare IPO?

(SRTS) raised $20 million in an IPO on Wednesday, March 30th 2016. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company served as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

What is Sensus Healthcare's stock symbol?

Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."

Who are Sensus Healthcare's major shareholders?

Sensus Healthcare's stock is owned by many different institutional and retail investors. Top institutional shareholders include Invenomic Capital Management LP (1.62%), Financial Engines Advisors L.L.C. (0.49%), Geode Capital Management LLC (0.42%), Citadel Advisors LLC (0.21%), Morgan Stanley (0.06%) and Morgan Stanley (0.06%).
View institutional ownership trends for Sensus Healthcare
.

Which institutional investors are selling Sensus Healthcare stock?

SRTS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Invenomic Capital Management LP, and Citadel Advisors LLC.
View insider buying and selling activity for Sensus Healthcare
or view top insider-selling stocks.

Which institutional investors are buying Sensus Healthcare stock?

SRTS stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and Financial Engines Advisors L.L.C..
View insider buying and selling activity for Sensus Healthcare
or or view top insider-buying stocks.

How do I buy shares of Sensus Healthcare?

Shares of SRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sensus Healthcare's stock price today?

One share of SRTS stock can currently be purchased for approximately $3.51.

How much money does Sensus Healthcare make?

Sensus Healthcare has a market capitalization of $58.34 million and generates $9.58 million in revenue each year. The company earns $-6,840,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does Sensus Healthcare have?

Sensus Healthcare employs 42 workers across the globe.

What is Sensus Healthcare's official website?

The official website for Sensus Healthcare is www.sensushealthcare.com.

Where are Sensus Healthcare's headquarters?

Sensus Healthcare is headquartered at 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487.

How can I contact Sensus Healthcare?

Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company can be reached via phone at (561) 922-5808 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.